T Cell Therapy Market Analysis Report - Size & Share 2030
[Research Report] The T cell therapy market size was valued at US$ 2,754.0 million in 2022 and is expected to reach US$ 9,035.01 million by 2030. It is estimated to register a CAGR of 16.0% during 2022–2030.
Market Insights and Analyst View:
One of the most promising procedures of cancer treatment is chimeric antigen receptor (CAR) T cell therapy, and every year, an increasing number of pre-clinical and clinical research is being conducted to increase its application. CAR T cell therapy has also generated interest among oncologists and academics. Immune checkpoint inhibitors are more common and widely used than CAR T cell treatments, even though CAR T cell therapy demonstrated the same capacity to destroy extremely advanced leukaemias and lymphomas and hold the disease away for many years. Hospitals are anticipated to adopt CAR-T cell therapy extensively; however, to deliver such therapy, the manufacturing and medical fields must set up an ecosystem for gathering raw materials, processing the product, dispensing it, and monitoring patients. The demand for T cell therapy is continuously growing due to the growing burden of cancer worldwide and an increasing number of T cell therapy approvals.
Companies operating in the T cell therapy market focus on strategic developments such as collaborations, agreements, and investments to improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. For instance, in August 2023, Astellas invested US$ 50 million in Poseida’s CAR T cell therapy. Astellas will have exclusive negotiation and first refusal for licensing P-MUC1C-ALLO1 in solid tumors as part of the agreement.
Growth Drivers and Challenges:
According to the World Health Organization (WHO), in 2020, cancer was a primary cause of death worldwide, account for ~10 million deaths. According to the International Agency for Research on Cancer, in 2040, 30.2 million new cases will be added to the global cancer burden. Chimeric antigen receptor (CAR) T cell therapies can potentially treat a new type of cancer treatment that uses the immune system to fight cancer. CAR T cells are innovative drugs that have turned the tables for treating hematologic malignancies, such as diffuse large B-cell lymphoma (DLBCL) and B-cell acute lymphoblastic leukemia (B-ALL) by achieving approval from the FDA based on their successful clinical outcomes. According to the Leukemia & Lymphoma Society, around one person every 3 minutes in the US is diagnosed with leukemia, lymphoma, or myeloma. In 2023, nearly 180,000 people in the US are expected to be diagnosed with lymphoma and leukemia.
T cell-based techniques are frequently used in cancer immunotherapy due to their higher success rate. In 2021, Labiotech.eu (a leading online media for the European biotech industry) stated that more than 500 CAR T cells clinical trials for cancer treatment are being carried out globally. Most are being carried out in East Asia, the US, and Europe. Thus, the growing burden of cancer is driving the T cell therapy market growth.
As CAR T cell therapy is complex, some high-risk side effects are associated. One of the most common and serious side effects caused by CAR T cell therapy is cytokine release syndrome (CRS). The other side effects of CAR T cell therapies are neurologic effects, including severe confusion, seizure-like activity, and impaired speech. Neurotoxicity is a side effect in most anti-CD19 CAR T cell therapy patients. ICANS is a common and challenging adverse effect of CAR T cell therapy, which occurs in 25–44% of children with hematologic malignancies. ICANS usually occurs within 7–10 days, sometimes up to 3 weeks after CAR T cell infusion and can occur concurrently or shortly after CRS. Thus, the challenges of side effects of the therapy limit the T cell therapy market growth.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
T Cell Therapy Market: Strategic Insights
Market Size Value in US$ 2,754.0 million in 2022 Market Size Value by US$ 9,035.01 million by 2030 Growth rate CAGR of 16.0% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
T Cell Therapy Market: Strategic Insights
| Market Size Value in | US$ 2,754.0 million in 2022 |
| Market Size Value by | US$ 9,035.01 million by 2030 |
| Growth rate | CAGR of 16.0% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope:
The “Global T cell therapy Market” is segmented based on the modality, therapy type, and indication. Based on the modality, segment into research and commercialized. In 2022, the commercialized segment held the larger share of the market. Based on therapy type, the T cell market is bifurcated into CAR T cell therapy and T cell receptor (TCR)-based. In terms of indication, the T cell therapy market is divided into hematologic malignancies and solid tumors. The T cell therapy market, based on geography, is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia Pacific (Australia, China, Japan, South Korea, and Rest of Asia Pacific), Middle East & Africa (Saudi Arabia, Israel, and Rest of Middle East & Africa), and South & Central America (Brazil).
Segmental Analysis:
By modality, the T cell therapy market is segmented into research and commercialized. In 2022, the commercialized segment held the largest share of the market. Moreover, the same segment is expected to grow fastest during the forecast period. An increase in product launches and a rise in awareness about the benefits of T cell therapy for cancer treatment fuelling the growth of the commercialized segment. Following are a few products commercialized for cancer treatment.
- In 2022, FDA approved CARVYKTI manufactured by Janssen Biotech, Inc. It is an autologous CAR-T cell engineered with lentivirus to attack BCMA-expressing tumor cells to treat certain kinds of refractory multiple myeloma.
- In January 2022, the US FDA approved a KIMMTRAK manufactured by Immunocare. It is used to treat unresectable or metastatic uveal melanoma.
Based on therapy type, the T cell therapy market is bifurcated into CAR T cell therapy and T cell receptor (TCR)-based. In 2022, the CAR T cell therapy segment held the larger share of the market. Moreover, the same segment will grow at a significant growth rate during the forecast period. In the chimeric antigen receptor (CAR) T cell therapy technique, T cells obtained from patients are artificially bioengineered to express CARs that can identify and attach to the tumour cells. The companies are entering into strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches by companies operating in the CAR T cell segment, fuelling the T cell therapy market growth. For instance, in 2022, FDA approved CARVYKTI manufactured by Janssen Biotech, Inc. CARVYKTI is a kind of therapy called CAR-T—which stands for chimeric antigen receptor T cell. CARVYKTI (ciltacabtagene autoleucel) is a treatment used for adult patients with bone marrow cancer called multiple myeloma. CARVYKTI treats adult patients with relapsed or refractory multiple myeloma after four or more former lines of therapy, comprising of a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
The T cell therapy market is divided into hematologic malignancies and solid tumors based on indication. In 2022, the hematologic malignancies segment held the largest market share; the same segment is projected to grow at a significant growth rate during the forecast period. Hematologic malignancies are cancer types that affect the human body's blood, bone marrow, and lymph nodes. Leukemia, lymphoma, myeloid, and myeloma are some hematologic malignancies. According to Leukemia and Lymphoma Society, in 2023, ~184,000 people in the US are expected to be diagnosed with leukemia, lymphoma, or myeloma. According to the same source, ~1.629,000 people in the US are affected by or in remission from hematologic malignancies. Due to an increase in the prevalence of hematologic malignancies worldwide, treatment approaches have developed rapidly.
Regional Analysis:
Based on geography, the T cell therapy market is divided into five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. The market in North America has been analyzed with a prime focus on three major countries—the US, Canada, and Mexico. North America held the largest T cell therapy market share in 2022. The T cell therapy market in North America is expected to grow due to the increasing burden of chronic disorders such as cancer and autoimmune disorders, growth in research and development activities, and strong and established market players. Also, with increased clinical studies in CAR T cell therapies, the market in North America is expected to grow during the forecast period.
T Cell Therapy Market Opportunity:
Growing Investment in T Cell Therapy
Companies operating in the T cell therapy market focus on strategic developments such as collaborations, expansions, agreements, and investment that help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few noteworthy developments in the T cell therapy market are mentioned below.
- In May 2023, Laurus Labs’ stake in ImmunoACT will now increase to 33.86% on a fully diluted basis post-completion of the deal. The company had already acquired 26.62% of stakes in ImmunoACT in November 2021. ImmunoACT has a portfolio of CAR T cell therapy assets under various development stages for treating multiple autoimmune diseases and oncology indications. This investment further strengthens Laurus Labs’ commitment to accessing novel Cell and Gene Therapy technology and enhances its affordability for patients. This investment will further help ImmunoACT to gear up for the manufacture of more treatments.
- In January 2023, the California Institute for Regenerative Medicine (CIRM) invested US$ 4 million to develop and test a CAR T cell therapy to treat various B-cell malignancies, ranging from lymphomas to leukemias.
- In November 2021, Autolus Therapeutics plc (a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies) and Blackstone Life Sciences entered into a collaboration and financing agreement under which funds are managed by Blackstone. Up to US$ 250 million in equity and product financing was provided by Blackstone to support Autolus’ development of its CD19 CAR T cell investigational therapy product, obecabtagene autoleucel (obe-cel), as well as the next-generation product therapies of obe-cel in B-cell malignancies.
Thus, these investments create lucrative opportunities in the T cell therapy market.
T Cell Therapy Market Report Scope
Competitive Landscape and Key Companies:
A few of the prominent players operating in the global T cell therapy market are Immunocore Holdings Plc, Legend Biotech Corp, Janssen Global Services LLC, Gilead Sciences Inc, Bristol-Myers Squibb Co, Bluebird Bio Inc, Novartis AG, JW (Cayman) Therapeutics Co Ltd, Cartesian Therapeutics Inc, and Innovent Biologics Inc. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. The companies implementing various inorganic and organic developments in the global T cell Therapy market. Below are few instance:
- In May 2023, Legend Biotech Corporation announced that a Type II variation application was submitted to the European Medicines Agency (EMA) for CARVYKTI based on data from the CARTITUDE-4 study (NCT04181827), which investigates the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma who have received one to three prior lines of therapy.
- In March 2023, JW Therapeutics, an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, has initiated the clinical study of Carteyva (relmacabtagene autoleucel injection) for first-line treatment in patients with high-risk large B-cell lymphoma and the first patient infusion.
- In June 2022, The U.S. Food and Drug Administration (FDA) approved Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Modality, Therapy Type, Indication, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The T cell therapy market, based on modality, is bifurcated into research and commercialized. In 2022, the commercialized segment held the largest share of the market. Moreover, same segment is expected to grow at the fastest rate during the coming years.
Asia Pacific is expected to be the fastest growing region in the T cell therapy market. The market in Asia Pacific is expected to witness significant growth as CAR T-cell therapy is efficient in treating cancer, elevating the market growth in the region. Many clinical trials for CAR T-cell therapy are ongoing in the region, offering new opportunities in APAC.
US holds the largest market share in T cell therapy market. The growth of the market in the country is due to the increasing burden of chronic disorders such as cancer and autoimmune disorders, growth in research and development activities, and strong and established market players.
One of the most promising procedures of cancer treatment is T cell therapy, and every year, an increasing number of pre-clinical and clinical research is being conducted to increase its application. CAR T cell therapy has also generated interest among oncologists and academics. Immune checkpoint inhibitors are more common and widely used than CAR T cell treatments, even though CAR T cell therapy demonstrated the same capacity to destroy extremely advanced leukemias and lymphomas and hold the disease away for many years.
The T cell therapy market majorly consists of the players such as Immunocore Holdings Plc, Legend Biotech Corp, Janssen Global Services LLC, Gilead Sciences Inc, Bristol-Myers Squibb Co, Bluebird Bio Inc, Novartis AG, JW (Cayman) Therapeutics Co Ltd, Cartesian Therapeutics Inc, and Innovent Biologics Inc. among others.
The factors that are driving growth of the market are growing burden of cancer worldwide and an increasing number of T cell therapy approvals.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 T Cell Therapy Market, by Geography (US$ Million)
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. T Cell Therapy Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. T Cell Therapy Market - Key Industry Dynamics
5.1 Market Drivers:
5.1.1 Growing Burden of Cancer Worldwide
5.1.2 Increasing Number of T-Cell Therapy Approvals
5.2 Market Restraints
5.2.1 Side-effects of CAR T-Cell Therapy
5.3 Market Opportunities
5.3.1 Growing Investment in T-Cell Therapy
5.4 Future Trends
5.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
5.5 Impact Analysis:
6. T Cell Therapy Market - Global Market Analysis
6.1 T Cell Therapy Market Revenue (US$ Mn), 2022 – 2030
7. Global T Cell Therapy Market – Revenue and Forecast to 2030 – by Modality
7.1 Overview
7.2 T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
7.3 Research
7.3.1 Overview
7.3.2 Research: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Commercialized
7.4.1 Overview
7.4.2 Commercialized: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8. Global T Cell Therapy Market – Revenue and Forecast to 2030 – by Therapy Type
8.1 Overview
8.2 T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
8.3 CAR T-cell Therapy
8.3.1 Overview
8.3.2 CAR T-cell Therapy: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.4 T-cell Receptor (TCR)-based
8.4.1 Overview
8.4.2 T-cell Receptor (TCR)-based: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9. Global T Cell Therapy Market – Revenue and Forecast to 2030 – by Indication
9.1 Overview
9.2 T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
9.3 Hematologic Malignancies
9.3.1 Overview
9.3.2 Hematologic Malignancies: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.3.3 Global T Cell Therapy Market, by Haematological Malignancies, 2020–2030 (US$ Million)
9.4 Solid Tumor
9.4.1 Overview
9.4.2 Solid Tumor: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
10. T Cell Therapy Market - Geographical Analysis
10.1 North America T Cell Therapy Market, Revenue and Forecast To 2030
10.1.1 Overview
10.1.2 North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.3 North America: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.1.4 North America: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.5 North America: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.5.1 North America: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.1.5.2 North America T Cell Therapy Market, by Country
10.1.5.3 US
10.1.5.3.1 US T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.5.3.2 US: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.1.5.3.3 US: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.5.3.4 US: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.5.3.4.1 US: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.1.5.4 Canada
10.1.5.4.1 Canada T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.5.4.2 Canada: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.1.5.4.3 Canada: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.5.4.4 Canada: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.5.4.4.1 Canada: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.1.5.5 Mexico
10.1.5.5.1 Mexico T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.5.5.2 Mexico: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.1.5.5.3 Mexico: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.5.5.4 Mexico: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.5.5.4.1 Mexico: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2 Europe T Cell Therapy Market, Revenue and Forecast to 2030
10.2.1 Overview
10.2.2 Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.3 Europe: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.4 Europe: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5 Europe: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.1 Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2.5.2 Europe T Cell Therapy Market, by Country
10.2.5.3 UK
10.2.5.3.1 UK T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.5.3.2 UK: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.5.3.3 UK: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5.3.4 UK: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.3.4.1 UK: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2.5.4 Germany
10.2.5.4.1 Germany T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.5.4.2 Germany: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.5.4.3 Germany: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5.4.4 Germany: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.4.4.1 Germany: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2.5.5 France
10.2.5.5.1 France T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.5.5.2 France: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.5.5.3 France: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5.5.4 France: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.5.4.1 France: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2.5.6 Italy
10.2.5.6.1 Italy T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.5.6.2 Italy: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.5.6.3 Italy: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5.6.4 Italy: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.6.4.1 Italy: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2.5.7 Spain
10.2.5.7.1 Spain T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.5.7.2 Spain: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.5.7.3 Spain: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5.7.4 Spain: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.7.4.1 Spain: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.2.5.8 Rest of Europe
10.2.5.8.1 Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.5.8.2 Rest of Europe: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.2.5.8.3 Rest of Europe: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.5.8.4 Rest of Europe: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5.8.4.1 Rest of Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.3 Asia Pacific T Cell Therapy Market, Revenue and Forecast to 2030
10.3.1 Overview
10.3.2 Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.3 Asia Pacific: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.3.4 Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.5 Asia Pacific: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5.1 Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.3.5.2 Asia Pacific T Cell Therapy Market, by Country
10.3.5.3 China
10.3.5.3.1 China T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.5.3.2 China: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.3.5.3.3 China: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.5.3.4 China: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5.3.4.1 China: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.3.5.4 Japan
10.3.5.4.1 Japan T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.5.4.2 Japan: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.3.5.4.3 Japan: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.5.4.4 Japan: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5.4.4.1 Japan: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.3.5.5 Australia
10.3.5.5.1 Australia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.5.5.2 Australia: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.3.5.5.3 Australia: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.5.5.4 Australia: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5.5.4.1 Australia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.3.5.6 South Korea
10.3.5.6.1 South Korea T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.5.6.2 South Korea: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.3.5.6.3 South Korea: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.5.6.4 South Korea: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5.6.4.1 South Korea: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.3.5.7 Rest of Asia Pacific
10.3.5.7.1 Rest of Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.5.7.2 Rest of Asia Pacific: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.3.5.7.3 Rest of Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.5.7.4 Rest of Asia Pacific: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5.7.4.1 Rest of Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.4 Middle East & Africa T Cell Therapy Market, Revenue and Forecast to 2030
10.4.1 Overview
10.4.2 Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.3 Middle East & Africa: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.4.4 Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5 Middle East & Africa: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.1 Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.4.5.2 Middle East & Africa T Cell Therapy Market, by Country
10.4.5.3 Saudi Arabia
10.4.5.3.1 Saudi Arabia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.3.2 Saudi Arabia: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.4.5.3.3 Saudi Arabia: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.3.4 Saudi Arabia: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.3.4.1 Saudi Arabia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.4.5.4 Israel
10.4.5.4.1 Israel T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.4.2 Israel: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.4.5.4.3 Israel: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.4.4 Israel: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.4.4.1 Israel: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.4.5.5 Rest of Middle East & Africa
10.4.5.5.1 Rest of Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.5.2 Rest of Middle East & Africa: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.4.5.5.3 Rest of Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.5.4 Rest of Middle East & Africa: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.5.4.1 Rest of Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
10.5 South & Central America T Cell Therapy Market, Revenue and Forecast to 2030
10.5.1 Overview
10.5.2 South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.2.1 Brazil
10.5.2.1.1 Brazil T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.2.1.2 Brazil: T Cell Therapy Market, by Modality, 2020–2030 (US$ Million)
10.5.2.1.3 Brazil: T Cell Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.2.1.4 Brazil: T Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.2.1.4.1 Brazil: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020–2030 (US$ Million)
11. T Cell Therapy Market–Industry Landscape
11.1 Overview
11.2 Growth Strategies in T Cell Therapy Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Immunocore Holdings Plc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Legend Biotech Corp
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Janssen Global Services LLC
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Gilead Sciences Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Bristol-Myers Squibb Co
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Bluebird Bio Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Novartis AG
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 JW (Cayman) Therapeutics Co Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Cartesian Therapeutics Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Innovent Biologics Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms
List of Tables
Table 1. T Cell Therapy Market Segmentation
Table 2. Global T Cell Therapy Market, by Hematological Malignancies – Revenue and Forecast to 2030 (US$ Million)
Table 3. North America T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 4. North America T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 5. North America T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 6. North America T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 7. US T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 8. US T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 9. US T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 10. US T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 14. Canada T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 19. Europe T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 20. Europe T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 21. Europe T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 22. Europe T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 23. UK T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 24. UK T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 25. UK T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 26. UK T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 27. Germany T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 28. Germany T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 29. Germany T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 30. Germany T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 31. France T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 32. France T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 33. France T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 34. France T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 35. Italy T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 36. Italy T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 37. Italy T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 38. Italy T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 39. Spain T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 40. Spain T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 41. Spain T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 42. Spain T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 43. Rest of Europe T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 44. Rest of Europe T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 45. Rest of Europe T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 46. Rest of Europe T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 47. FDA-Approved Autologous CAR T-Cell Therapies Registered in Asia Pacific
Table 48. Asia Pacific T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 49. Asia Pacific T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 50. Asia Pacific T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 51. Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 52. China T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 53. China T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 54. China T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 55. China T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 56. Japan T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 57. Japan T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 58. Japan T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 59. Japan T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 60. Australia T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 61. Australia T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 62. Australia T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 63. Australia T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 64. South Korea T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 65. South Korea T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 66. South Korea T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 67. South Korea T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 68. Rest of Asia Pacific T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 69. Rest of Asia Pacific T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 70. Rest of Asia Pacific T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 71. Rest of Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 72. Middle East & Africa T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 73. Middle East & Africa T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 74. Middle East & Africa T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 75. Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 76. Saudi Arabia T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 77. Saudi Arabia T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 78. Saudi Arabia T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 79. Saudi Arabia T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 80. Israel T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 81. Israel T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 82. Israel T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 83. Israel T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 84. Rest of Middle East & Africa T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 85. Rest of Middle East & Africa T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 86. Rest of Middle East & Africa T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 87. Rest of Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 88. Brazil T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 89. Brazil T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 90. Brazil T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 91. Brazil T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 92. Recent Organic Growth Strategies in T Cell Therapy Market
Table 93. Recent Inorganic Growth Strategies in the T Cell Therapy Market
Table 94. Glossary of Terms, T Cell Therapy Market
List of Figures
Figure 1. T Cell Therapy Market Segmentation, By Geography
Figure 2. Global - PEST Analysis
Figure 3. T Cell Therapy Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. T Cell Therapy Market Revenue (US$ Mn), 2022 – 2030
Figure 6. T Cell Therapy Market Revenue, Geography (US$ Mn), 2022 – 2030
Figure 7. T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 8. Research: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Commercialized: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 11. CAR T-cell Therapy: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. T-cell Receptor (TCR)-based: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 14. Hematologic Malignancies: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Solid Tumor: T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America: T Cell Therapy Market, by Key Country – Revenue (2022) (US$ Million)
Figure 17. North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. North America T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 19. US T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. Canada T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Mexico T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Europe T Cell Therapy Market, by Key Country – Revenue, 2022 ($Mn)
Figure 23. Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Europe T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 25. UK T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Germany T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 27. France T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Italy T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. Spain T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. Asia Pacific T Cell Therapy Market, by Key Country – Revenue, 2022 ($Mn)
Figure 32. Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 33. Asia Pacific T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 34. China T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 35. Japan T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 36. Australia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 37. South Korea T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 38. Rest of Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 39. Middle East & Africa T Cell Therapy Market, by Key Country – Revenue, 2022
Figure 40. Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 41. Middle East & Africa T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 42. Saudi Arabia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 43. Israel T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 44. Rest of Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 45. South & Central America T Cell Therapy Market, by Key Country – Revenue, 2022 ($Mn)
Figure 46. South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 47. Brazil T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 48. Pre & Post Covid-19 Impact
Figure 49. Growth Strategies in T Cell Therapy Market
The List of Companies - T Cell Therapy Market
- Immunocore Holdings Plc
- Legend Biotech Corp
- Janssen Global Services LLC
- Gilead Sciences Inc
- Bristol-Myers Squibb Co
- Bluebird Bio Inc
- Novartis AG
- JW (Cayman) Therapeutics Co Ltd
- Cartesian Therapeutics Inc
- Innovent Biologics Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For